Marker Therapeutics Inc (MRKR): Market Cap to Revenue

Corporate company logo of Marker Bio (MRKR)

Marker Therapeutics is developing innovative T-cell therapy against leukemia, expanding treatment access via MultiTAA technology. Government grants provide stability by curbing capital expenditure. This chart on GURU.Markets provides a visual representation of P/S, where 6.10 serves as the final level marker. However, production scaling challenges and potential side effects during trials create certain financial risks.

Price-to-Revenue Ratio: Marker Therapeutics Inc (MRKR) for 07/04/2022 - 11/16/2026

Analytical breakdowns for Marker Therapeutics (MRKR)

- stock price and consensus target price:
- stock exchange capitalization data:
Fundamental company analysis:markertherapeutics.com, MRKR
Signature product of Marker Bio

Marker Therapeutics is integrating ESG principles into the development of cell therapies by optimizing laboratory sustainability. The price-to-sales ratio trend captures the gap between market capitalization and actual cash flow. This metric compares the share price to sales volume, determining the investor's premium paid per unit of revenue. Sharp peaks on the chart signal speculative growth, creating the risk of a substantial correction in asset value.